ALACHUA, Fla., March 26, 2012 (GLOBE NEWSWIRE) -- NanoSonic Products, Inc., a wholly owned subsidiary of CTD Holdings, Inc. (OTCQB:CTDH), announced that the Company has signed an exclusive distribution agreement with Uno Healthcare of Miami, FL for its Trappsol Cyclo products in the territories of Brazil and Columbia, South America. Trappsol Cyclo is designated as an orphan drug for the treatment of Niemann Pick Type-C disease, also known as Childhood Alzheimer's, which affects children and adults resulting in progressive neurological degeneration.
"Uno Healthcare is a leader in the distribution of specialty pharmaceuticals in South American markets," stated NanoSonic Products President and CEO, Dr. Jeffrey Tate, "This agreement reinforces our commitment to be sure that Trappsol Cyclo gets to the sick children who will benefit from its use."
Trappsol Cyclo is the world's only API-grade cyclodextrin product. As it develops, it will be the lead product for Sphingo Biotechnology, Inc. another wholly owned division of CTD Holdings, Inc. exclusively focused on the development of API-grade cyclodextrins for pharmaceutical applications.
To receive timely information on CTD Holdings, Inc. when it hits the newswire, sign up for CTD Holdings' email news alert system today at: www.ctd-holdings.com/alert
About NanoSonic Products, Inc.:
NanoSonic Products, Inc. is part of the CTD Holdings, Inc. family of companies. CTD Holdings companies manufacture and market Trappsol and Aquaplex cyclodextrins and cyclodextrin complexes for food, nutrition and pharmaceutical markets. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of pharmaceutical grade Aquaplex cyclodextrin complexes. The company offers a wide variety of cyclodextrin related manufacturing services to its worldwide customers including: custom formulation, cyclodextrin complex development, and commercial scale supply of pharmaceutical grade cyclodextrin complexes.
About Uno Healthcare
UNO Healthcare is a licensed distributor of pharmaceuticals devoted to licensing pharmaceuticals and acquiring their rights for distribution to countries in Latin America. Our distribution network relies on our experienced sales representatives and our knowledgeable partners located in each country. We source and supply pharmaceuticals to governmental agencies, hospitals, and physicians.
Safe Harbor Statement: This news release contains "forward-looking statements" about the Company's anticipated growth. You are cautioned that such statements are subject to risks and uncertainties and that could cause actual results to differ materially from those projected in the forward-looking statements, such as the Company's ability to obtain additional capital to expand operations as planned. The above forward-looking statements are made as of the date above; CTD Holdings, Inc. accepts no specific responsibility for updating such statements.
CONTACT: Investor Relations Contact: Sean Marconi The WSR Group (772) 219-7525 email@example.com http://www.wallstreetresources.net/CTDHoldings.aspSource: CTD Holdings, Inc.